Adult brainstem gliomas: Correlation of clinical and molecular features

[1]  D. Reardon,et al.  Adult brainstem gliomas , 2016, Cancer.

[2]  N. Martin-Duverneuil,et al.  Temozolomide after radiotherapy in recurrent “low grade” diffuse brainstem glioma in adults , 2014, Journal of Neuro-Oncology.

[3]  J. Slopis,et al.  Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab , 2014, Journal of Neurology.

[4]  R. McLendon,et al.  Malignant brainstem gliomas in adults: clinicopathological characteristics and prognostic factors , 2014, Journal of Neuro-Oncology.

[5]  R. Stupp,et al.  Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients , 2014, Journal of Neuro-Oncology.

[6]  Dima Suki,et al.  Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Trippel,et al.  Retrospective analysis of 104 histologically proven adult brainstem gliomas: clinical symptoms, therapeutic approaches and prognostic factors , 2014, BMC Cancer.

[8]  I. Vajtai,et al.  Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co‐deletion , 2014, Neuropathology : official journal of the Japanese Society of Neuropathology.

[9]  A. Friedman,et al.  Clinical characteristics and treatment of malignant brainstem gliomas in elderly patients , 2013, Journal of Clinical Neuroscience.

[10]  M. Chamberlain,et al.  Brainstem Glioma: A Review , 2013, Current Neurology and Neuroscience Reports.

[11]  M. Pinsker,et al.  Bevacizumab as salvage therapy for progressive brain stem gliomas , 2013, Clinical Neurology and Neurosurgery.

[12]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[13]  K. Aldape,et al.  Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas , 2012, Acta Neuropathologica.

[14]  A. Unterberg,et al.  No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas , 2012, Journal of Neuro-Oncology.

[15]  L. Macconaill,et al.  Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma , 2012, Pediatric blood & cancer.

[16]  S. Blond,et al.  Correlation between magnetic resonance imaging findings and histological diagnosis of intrinsic brainstem lesions in adults. , 2012, Neuro-oncology.

[17]  P. Varlet,et al.  Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas , 2012, PloS one.

[18]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[19]  Zhaoshi Jiang,et al.  Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Reifenberger,et al.  Patients with IDH 1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH 1-mutated glioblastomas , and IDH 1 mutation status accounts for the unfavorable prognostic effect of higher age : implications for classification of gliomas , 2010 .

[21]  K. Hoang-Xuan,et al.  All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 , 2010, Neurology.

[22]  M. Rotman,et al.  Characterization and outcomes of infratentorial malignant glioma: a population-based study using the Surveillance Epidemiology and End-Results database. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[24]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[25]  M. J. van den Bent,et al.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Mikkelsen,et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Tonn,et al.  Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[28]  Ryung S. Kim,et al.  Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases , 2008, Journal of Neuro-Oncology.

[29]  Susan M. Chang,et al.  Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Hoang-Xuan,et al.  MGMT methylation: A marker of response to temozolomide in low‐grade gliomas , 2006, Annals of neurology.

[31]  S. Donaldson,et al.  Advances toward an understanding of brainstem gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[33]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[34]  J J Mazeron,et al.  Brainstem gliomas in adults: prognostic factors and classification. , 2001, Brain : a journal of neurology.

[35]  M. Souweidane,et al.  Brainstem Gliomas , 2007 .

[36]  张静,et al.  Banana Ovate family protein MaOFP1 and MADS-box protein MuMADS1 antagonistically regulated banana fruit ripening , 2015 .

[37]  M. Sanson,et al.  Molecular analysis of diffuse intrinsic brainstem gliomas in adults , 2013, Journal of Neuro-Oncology.

[38]  M. J. van den Bent,et al.  Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? , 2011, The Lancet. Oncology.

[39]  M. Prados,et al.  Radiologic classification of brain stem tumors: correlation of magnetic resonance imaging appearance with clinical outcome. , 1996, Pediatric neurosurgery.